Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.12 USD

96.12
370,120

+0.08 (0.08%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy

The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.

    Boston Scientific MultiSENSE Study on HeartLogic Positive

    Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.

      Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care

      Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.

        Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1

        Neogen (NEOG) rides high on balanced growth across all business segments.

          Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5

          Varian Medical (VAR) is consistently trying to turn around its Oncology Systems business.

            Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?

            Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.

              5 MedTech Stocks to Pick for Stellar Returns

              While the MedTech industry has been grappling with multiple issues, these stocks with high growth potential can be great bets.

                Why the Earnings Streak Will Continue for Amedisys (AMED)

                Amedisys (AMED) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.

                  Inovalon Holdings' ONE Platform Chosen by UnitedHealthcare

                  Inovalon Holding (INOV) will be able to expand in the population health management space through the selection of its proprietary ONE Platform by UnitedHealthcare.

                    Fresenius Medical Opens Manufacturing Plant in Malaysia

                    Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.

                      Amedisys Rides High on Strong Prospects Amid Margin Woes

                      Strength in Hospice and Personal Care businesses are offsetting the weakness in Amedisys' (AMED) Home Health Medicare business.

                        Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm

                        Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.

                          IDEXX Laboratories Rides High on Strong CAG, Global Growth

                          IDEXX (IDXX) rides high on balanced segmental growth with significant contributions from the Companion Animal Group business. Moreover, strong fundamentals buoy optimism.

                            Medtronic Launches StealthStation Technology, Expands in ENT

                            Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.

                              Centene's Fidelis Care Buyout to Expand Presence in New York

                              Centene's (CNC) acquisition of Fidelis Care for $3.75 billion for expanding in New York, is expected to impact Centene's top line and bottom line positively.

                                5 Discounted MedTech Stocks for a Healthy Portfolio

                                In view of the current political scenario and banking on favorable metrics, these five MedTech stocks stand out as the most suitable value picks.

                                  Universal Health (UHS) Grows on Buyouts, Expenses a Drag

                                  Despite solid revenue growth backed by inorganic strategies, Universal Health's (UHS) rising level of debt and expenses continue to weigh on margins.

                                    Top Ranked Growth Stocks to Buy for September 11th

                                    Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, September 11th:

                                      Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm

                                      Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.

                                        3 Excellent Value Picks as Political Chaos Grips MedTech

                                        In view of the current political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable value picks.

                                          Ensign Group's Inorganic Growth Impresses, Debt Level Hurts

                                          Ensign Group's (ENSG) top line rises on inorganic and organic growth. Its financial health also impresses. However high level of costs and debts bother.

                                            Molina Healthcare's Top Line Grows on Membership, Debts Hurt

                                            Molina Healthcare's (MOH) top line benefits from inorganic growth and membership. However, rising level of debt and expenses hurt margins.

                                              WellCare Health Partners Mission Health to Improve Offerings

                                              WellCare Health Plans, Inc's (WCG) subsidiary, Wellcare of North Carolina recently entered into an agreement with Mission Health to provide better Medicaid and Medicare services in North Carolina.

                                                Centene (CNC) Poised to Grow on Buyouts, High Debt Bothers

                                                Centene's (CNC) accretive acquisitions backed by solid financials add to its top line. However, high debt and rising expenses hurt margins.

                                                  Amedisys (AMED) Up 3.6% Since Earnings Report: Can It Continue?

                                                  Amedisys (AMED) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.